We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Kymera Therapeutics
KYMR
$9.1B
| $19.9M | 0.14% |
410,991
+410,984
| +5,871,200% | +$17.8M |
|
177
HP
HPQ
$23.5B
| $19.9M | 0.14% |
659,150
+331,682
| +101% | +$10.6M |
|
178
Kura Oncology
KURA
$922M
| $19.7M | 0.14% |
946,357
+17,080
| +2% | +$424K |
|
179
Kinder Morgan
KMI
$73.1B
| $19.7M | 0.13% |
1,079,768
+374,097
| +53% | +$6.67M |
|
180
SolarEdge
SEDG
$2.59B
| $19.5M | 0.13% |
70,728
-17,466
| -20% | -$4.4M |
|
181
Bank of Montreal
BMO
$125B
| $19.4M | 0.13% |
188,625
+165,763
| +725% | +$16.4M |
|
182
Arvinas
ARVN
$518M
| $19.3M | 0.13% |
250,603
-38,811
| -13% | -$2.69M |
|
183
Cerence
CRNC
$382M
| $19.3M | 0.13% |
+180,600
| New | +$17.8M |
|
184
Crown Castle
CCI
$32.7B
| $19.2M | 0.13% |
98,606
+24,630
| +33% | +$4.61M |
|
185
Hilton Worldwide
HLT
$74B
| $18.9M | 0.13% |
156,388
+130,332
| +500% | +$16.3M |
|
186
MasTec
MTZ
$26.7B
| $18.8M | 0.13% |
+177,548
| New | +$19.3M |
|
187
Replimune Group
REPL
$814M
| $18.7M | 0.13% |
485,988
+323,828
| +200% | +$11.1M |
|
188
lululemon athletica
LULU
$13B
| $18.4M | 0.13% |
50,313
+9,529
| +23% | +$3.14M |
|
189
Travelers Companies
TRV
$80.8B
| $18.3M | 0.13% |
122,280
+135
| +0.1% | +$20.9K |
|
|
PPD
190
DELISTED
PPD, Inc. Common Stock
PPD
| $18.3M | 0.13% |
+396,971
| New | +$17.9M |
|
|
MGLN
191
DELISTED
Magellan Health Services, Inc.
MGLN
| $18.3M | 0.13% |
+193,817
| New | +$18.3M |
|
192
Align Technology
ALGN
$12B
| $18.1M | 0.12% |
29,545
+25,081
| +562% | +$14.8M |
|
|
XLNX
193
DELISTED
Xilinx Inc
XLNX
| $18M | 0.12% |
124,372
+33,976
| +38% | +$4.32M |
|
|
TLND
194
DELISTED
Talend S.A. American Depositary Shares
TLND
| $17.6M | 0.12% |
+268,728
| New | +$17.4M |
|
|
DOCU
195
DocuSign
DOCU
$9.63B
| $17.6M | 0.12% |
63,014
+49,606
| +370% | +$11.1M |
|
|
LMNX
196
DELISTED
Luminex Corp
LMNX
| $17.6M | 0.12% |
+478,532
| New | +$17.4M |
|
197
Kroger
KR
$34.8B
| $17.6M | 0.12% |
459,474
+263,910
| +135% | +$9.93M |
|
198
Intel
INTC
$466B
| $17.6M | 0.12% |
312,880
-364,514
| -54% | -$21.4M |
|
199
Bilibili
BILI
$7.18B
| $17.5M | 0.12% |
143,950
-198,048
| -58% | -$21.5M |
|
200
Xencor
XNCR
$1.44B
| $17.4M | 0.12% |
504,544
-10,868
| -2% | -$431K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.